Published in Pharmaceuticals (Basel) on November 25, 2013
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol (2015) 1.53
Monitoring Intact Viruses Using Aptamers. Biosensors (Basel) (2016) 0.94
Site specific replacements of a single loop nucleoside with a dibenzyl linker may switch the activity of TBA from anticoagulant to antiproliferative. Nucleic Acids Res (2015) 0.81
Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses. Pharmaceuticals (Basel) (2016) 0.79
Fitness Landscapes of Functional RNAs. Life (Basel) (2015) 0.79
EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics (2015) 0.79
Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharm Sci (2017) 0.75
Aptamers against pathogenic microorganisms. Crit Rev Microbiol (2015) 0.75
Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrob Agents Chemother (2017) 0.75
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 24.78
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med (2012) 22.75
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science (1985) 12.75
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell (1989) 9.68
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Internal ribosome entry site within hepatitis C virus RNA. J Virol (1992) 9.14
Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio (2012) 8.54
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Fidelity of HIV-1 reverse transcriptase. Science (1988) 8.08
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis (2000) 6.54
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell (1989) 6.28
Influenza. Lancet (2003) 6.08
Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature (1990) 5.68
Regulatory pathways governing HIV-1 replication. Cell (1989) 4.97
The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell (1992) 4.72
Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science (1998) 4.52
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci (1998) 3.78
Retrovirus budding. Virus Res (2004) 3.66
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol (1994) 3.51
RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A (1992) 3.46
Aptamers come of age - at last. Nat Rev Microbiol (2006) 3.33
C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun (1995) 3.09
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 2.59
The emerging field of RNA nanotechnology. Nat Nanotechnol (2010) 2.45
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
HIV-1 attachment: another look. Trends Microbiol (1999) 2.23
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Tat and Rev: positive regulators of HIV gene expression. AIDS (1990) 2.18
Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell (1991) 2.05
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A (2001) 2.02
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci (1993) 1.99
Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol (1988) 1.95
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc Natl Acad Sci U S A (2005) 1.71
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem (1986) 1.70
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
Pathology and epidemiology of HPV infection in females. Gynecol Oncol (2010) 1.62
DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2. DNA (1984) 1.62
Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov (2005) 1.59
Serologic study for influenza A (H7N9) among high-risk groups in China. N Engl J Med (2013) 1.59
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem (1998) 1.57
Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci (2012) 1.56
Molecular mechanisms in retrovirus DNA integration. Antiviral Res (1997) 1.54
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation (2007) 1.51
RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends Biochem Sci (1993) 1.50
Human papillomaviruses, cervical cancer and cell polarity. Oncogene (2008) 1.47
The changing nature of avian influenza A virus (H5N1). Trends Microbiol (2011) 1.46
1918 Spanish influenza: the secrets remain elusive. Proc Natl Acad Sci U S A (1999) 1.42
Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41
Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics (2000) 1.40
Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J Virol (2003) 1.37
Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene (2003) 1.36
High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry (1995) 1.34
Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther (2007) 1.34
DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol (2002) 1.34
Generating aptamers for recognition of virus-infected cells. Clin Chem (2009) 1.31
An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J Gen Virol (2006) 1.29
The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J (1998) 1.27
Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance. Anal Biochem (2005) 1.26
Cancer associated human papillomaviruses. Curr Opin Virol (2012) 1.25
Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA (2013) 1.24
In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA (1999) 1.24
Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS (1996) 1.24
Getting a grip: polymerases and their substrate complexes. Curr Opin Struct Biol (1999) 1.23
Understanding HSV-1 entry glycoproteins. Rev Med Virol (2007) 1.22
Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int (2011) 1.21
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
HIV-1 inactivation by nucleic acid aptamers. Front Biosci (2006) 1.21
The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett (2002) 1.20
HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem (2000) 1.19
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol (2010) 1.18
Pathogenesis of rabies. Curr Top Microbiol Immunol (2005) 1.18
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
DNA aptamers selected against the HIV-1 trans-activation-responsive RNA element form RNA-DNA kissing complexes. J Biol Chem (1999) 1.17
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res (2002) 1.16
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2002) 1.15
Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA (2005) 1.13
Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 1.13
An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol (2005) 1.12
AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther (2010) 1.10
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Functional siRNA expression from transfected PCR products. RNA (2002) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29
RNAi and the P-body connection. Nat Cell Biol (2005) 1.29
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res (2008) 1.25
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Expressing short hairpin RNAs in vivo. Nat Methods (2006) 1.14
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res (2010) 1.11
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08
Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
Control of HIV-1 replication by RNA interference. Virus Res (2004) 1.05
Amplification of RNAi--targeting HLA mRNAs. Mol Ther (2005) 1.05
Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev (2003) 1.04
Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04
Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 1.03
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem (2009) 0.99
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. Org Biomol Chem (2007) 0.98
Progress in RNAi-based antiviral therapeutics. Methods Mol Biol (2011) 0.98
Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). J Mol Cell Cardiol (2004) 0.98
Epigenetics and microRNAs. Pediatr Res (2007) 0.98
Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. Anal Chem (2012) 0.98
Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther (2006) 0.98
Sensing the danger in RNA. Nat Med (2005) 0.97
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol (2011) 0.94
Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther (2004) 0.93
Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol (2008) 0.93
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93